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Abstract: Burkholderia pseudomallei, a bacterium that causes the disease melioidosis, is 
intrinsically resistant to many antibiotics. First-line antibiotic therapy for treating melioidosis 
is usually the synthetic β-lactam, ceftazidime (CAZ), as almost all B. pseudomallei strains are 
susceptible to this drug. However, acquired CAZ resistance can develop in vivo during treat-
ment with CAZ, which can lead to mortality if therapy is not switched to a different drug in a 
timely manner. Serial B. pseudomallei isolates obtained from an acute Thai melioidosis patient 
infected by a CAZ susceptible strain, who ultimately succumbed to infection despite being on 
CAZ therapy for the duration of their infection, were analyzed. Isolates that developed CAZ 
resistance due to a proline to serine change at position 167 in the β-lactamase PenA were identi-
fied. Importantly, these CAZ resistant isolates remained sensitive to the alternative melioidosis 
treatments; namely, amoxicillin-clavulanate, imipenem, and meropenem. Lastly, real-time 
polymerase chain reaction-based assays capable of rapidly identifying CAZ resistance in B. 
pseudomallei isolates at the position 167 mutation site were developed. The ability to rapidly 
identify the emergence of CAZ resistant B. pseudomallei populations in melioidosis patients 
will allow timely alterations in treatment strategies, thereby improving patient outcomes for 
this serious disease.
Keywords: Burkholderia pseudomallei, ceftazidime, antibiotic resistance, melioidosis, 
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Introduction
Burkholderia pseudomallei is the etiologic agent of melioidosis, a disease endemic 
to Southeast Asia and northern Australia that is becoming increasingly identified in 
other tropical regions throughout the world.1 B. pseudomallei is intrinsically resis-
tant to several antimicrobial agents, limiting treatment options for melioidosis.2,3 
In Thailand, confirmed melioidosis cases are typically treated with intravenous 
 ceftazidime (CAZ), a third-generation cephalosporin that is routinely administered for 
a minimum of 10 days, or considerably longer for complex, deep-seated infections.4 
CAZ is also routinely administered for suspected melioidosis cases, and for confirmed 
cases prior to the availability of antimicrobial susceptibility data, on the basis that 
primary CAZ resistance is rare.2,5 However, recent reports have demonstrated that 
CAZ resistance can arise in vivo following chemotherapy,3,5–9 especially where 
CAZ has been administered on multiple occasions, such as in relapse melioidosis 
cases.5 Early detection of B. pseudomallei resistance towards clinically relevant 
antibiotics such as CAZ is thus an important factor in reducing the morbidity and 
mortality of melioidosis.
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Several molecular mechanisms for CAZ resistance have 
been reported in the B. pseudomallei literature, all of which 
have been shown to arise in vivo following CAZ  administration. 
A single-nucleotide polymorphism (SNP) in the promoter 
region of the β-lactamase gene, penA (-21) has been shown 
to cause upregulation of PenA elevating the CAZ minimum 
inhibitory concentration (MIC) from 1.5 µg/mL in wild-type B. 
pseudomallei to 6–16 µg/mL in PenA -21A mutants depending 
on the strain.5,10 Within the penA coding sequence, amino 
acid substitutions at positions 695,7 and 16711 lead to mark-
edly increased CAZ hydrolysis compared with wild-type B. 
pseudomallei isolates (MIC values of $256 µg/mL and 64 µg/
mL for cysteine to tyrosine at position 69 [C69Y] and proline 
to serine at position 167 [P167S] mutants, respectively). Lastly, 
a large chromosomal deletion encompassing penicillin-binding 
protein-3 causes the loss of a CAZ-binding cell-surface mol-
ecule, resulting in high-level CAZ resistance (MIC $ 256 µg/
mL).6
Case study
Forty B. pseudomallei isolates obtained from a single Thai 
patient (P45) with acute, nonresolving melioidosis were tested 
for CAZ resistance. P45, a 51-year-old male rice farmer, 
presented with a leg abscess and high fever and was treated 
on admission with intravenous ceftriaxone and clindamycin 
for 1 day, then switched to intravenous CAZ after confirma-
tion of B. pseudomallei by an immunofluorescence assay.12 
P45 initially responded well to therapy, but after 2 weeks of 
treatment he had a marked deterioration associated with the 
development of hypotension, dyspnea, recurrence of fever, 
and pleural effusion on chest radiography. Despite continued 
CAZ therapy, P45 subsequently died. It was demonstrated 
previously that the B. pseudomallei isolates obtained from 
P45 were clonal.13 Thus, having ruled out coinfection or 
reinfection, it was suspected that in vivo development of CAZ 
resistance may have accounted for treatment failure in P45.
Materials and methods
Ethics statement
Informed written consent for genetic studies of these isolates 
was provided by the patient and approved by the Human 
Research Ethics Committee of the Faculty of Tropical 
Medicine, Mahidol University (Bangkok, Thailand).14
Culture conditions and antibiotic 
sensitivity testing
B. pseudomallei isolates were grown as described elsewhere.5 
MIC values for CAZ, amoxicillin-clavulanate, imipenem, 
and meropenem were determined using Etest® (bioMerieux 
SA, Marcy l’Etoile, France) according to manufacturer’s 
instructions. CAZ MIC values for susceptible, intermediate 
resistant, and resistant cutoffs were defined as #8 µg/mL, 
16 µg/mL, and $32 µg/mL, respectively.2
SYBR Green-based mismatch amplification 
mutation assay (SYBR-MAMA)
SYBR-MAMA polymerase chain reaction setups and 
thermocycling conditions were carried out as described 
elsewhere.5 The primers were as follows: penAP167S_ForM 
(5′-TTTTTTTTTTTTTTTAGCGCCGTGTTCAGCTCAtA) 
and penAP167S_RevM (5′-GCGACGTTCCGGCTC-
GAT) to amplify the mutant allele; penAP167S_ForWT 
(5′- GCCCGCCCGCCCGCCCGCGCCGTGTTCAGCT-
CAtG) and penAP167S_RevWT (5′-CGACGTTCCG-
GCTCGATC) to interrogate the wild-type SNP state. 
Lowercase nucleotides indicate deliberately incorporated 
antepenultimate mismatches;15 underlined nucleotides 
represent the SNP. All samples were run in duplicate, and 
no-template controls were included in every run.
Results
The initial 30 B. pseudomallei isolates collected upon P45’s 
admission to hospital were sensitive to CAZ (2 µg/mL) as 
determined by Etest. However, ten isolates collected 18 days 
later showed a predominately CAZ-resistant collection of 
nine strains (64 µg/mL), with a single susceptible strain. 
Given that the CAZ-resistant strains possessed MIC values 
similar to those from PenAP167S-mutated B. pseudomallei 
strains,11 it was expected that the latter P45 B. pseudomallei 
isolates would possess the same penA mutation. Sanger 
sequencing of penA from representative sensitive and 
resistant isolates confirmed a P167S substitution (Ambler’s 
numbering scheme)16 (Figure 1).
A SYBR-MAMA17 was developed to rapidly interrogate 
the mutant and wild-type variants at PenA 167 in the remain-
ing P45 isolates. The PenA 167 SYBR-MAMA readily dis-
criminated between mutant and wild-type alleles  (Figure 2). 
In all cases, the PenA 167 genotype corresponded with the 
CAZ MIC; CAZ-susceptible strains (2 µg/mL) exhibited 
preferential amplification of the wild-type allele (Figure 2, 
left panel) and CAZ-resistant isolates preferentially amplified 
the mutant PenA 167 allele (Figure 2, right panel).
It has been previously shown that upregulatory penA 
promoter mutations that increase CAZ resistance can 
also confer cross-resistance to the alternative treatments 
for melioidosis; namely, amoxicillin-clavulanate and 
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Figure 1 DNA alignments of penA from patient 45 wild-type and mutant alleles against three other wild-type Burkholderia pseudomallei strains – K96243, 1710b, and 
668 – showing a cytosine/thymine nucleotide transition at position 517 (according to penA annotation in B. pseudomallei K96243).22 
Note: This transition results in an amino acid substitution from proline to serine at position 167 in PenA.
Abbreviation: P45, patient 45.
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Figure 2 SYBR Green mismatch amplification mutation assay interrogation of the proline to serine at position 167 (P167S) PenA mutation, conferred by a cytosine/
thymine nucleotide transition in penA at position 517 (according to penA annotation in Burkholderia pseudomallei K96243;22 see Figure 1) in patient 45 B. pseudomallei isolates. 
(A) Example amplification of the wild-type P167S penA allele. (B) Example amplification of the mutated P167S penA allele. All mutant P167S B. pseudomallei strains from patient 
45 contained an elevated ceftazidime minimum inhibitory concentration of 64 µg/mL compared with the wild-type strains (2 µg/mL).
Abbreviation: Wt, wild-type.
imipenem.5,18 Therefore, the effect of the PenA P167S 
substitution on other β-lactam and carbapenem antibiotics 
commonly used to treat melioidosis was examined to 
determine whether this mutation also caused cross-resistance 
in this isolate. MIC values for amoxicillin-clavulanate, 
imipenem, and meropenem were determined for two CAZ-
susceptible and CAZ-resistant B. pseudomallei isolates from 
P45 using Etest. Both the wild-type and mutated isolates 
remained susceptible to these alternate treatment options 
(MIC value: meropenem = 1 µg/mL;  imipenem = 0.5 µg/mL; 
amoxicillin-clavulanate = 1.5 µg/mL), demonstrating that the 
P167S substitution had no effect on these alternate treatment 
strategies.
Discussion
The in vivo development of antibiotic resistance can have 
serious consequences on patient outcomes and is especially 
problematic where treatment options are already limited. For 
B. pseudomallei, development of resistance to the  first-line 
antibiotic, CAZ, is becoming increasingly recognized 
as an important cause of treatment failure and infection 
relapse. Melioidosis cases reporting CAZ-resistant in vivo 
B. pseudomallei populations have now been described in 
Southeast Asia, India, Taiwan, and Australia.5,6,8,9 Given 
the protracted and lengthy regimen required for effective 
treatment of melioidosis, and the occurrence of relapse/
recrudescent cases in ∼6% of patients,19,20 the development 
of in vivo CAZ resistance is potentially more common than 
first thought.
In the current study, the molecular basis behind treat-
ment failure in an acute case of melioidosis in Thailand that 
lead to patient mortality was identified. The P167S mutation 
appeared to only increase CAZ hydrolysis, with this study 
and others showing that ceftriaxone, imipenem, meropenem, 
and amoxicillin-clavulanate MIC values are unaffected by 
this mutation.11,18 Therefore, the development of the P167S 
mutation among the P45 in vivo B. pseudomallei population 
was most likely a result of CAZ administration. Nine out of 
ten colonies obtained from P45 following melioidosis relapse 
were CAZ resistant after 17 days of treatment with this drug, 
indicating strong positive selection of the P167S mutation 
under CAZ treatment.
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Elucidation of resistance mechanisms towards clini-
cally relevant antibiotics is crucial in determining effective 
treatment regimens for melioidosis. A real-time polymerase 
chain reaction assay that enables the rapid detection of P167S 
B. pseudomallei CAZ mutants in vivo is herein described. 
The availability of real-time assays for resistance detection 
allows clinicians to monitor infection dynamics and thus alter 
chemotherapy in real time, leading to more effective antimi-
crobial treatments and better patient outcomes. In addition, 
this study further challenges the dogma that a single isolate 
is representative of the in vivo bacterial population dynam-
ics.13,21 It was demonstrated that such practices can lead to 
erroneous assumptions regarding antibiotic resistance, as one 
out of ten isolates collected from P45 18 days after admission 
still possessed a CAZ-sensitive phenotype.
It is recommended that in acute nonresolving melioidosis 
cases, good clinical practice should entail collection and 
characterization of multiple clinical specimens from multiple 
time points, where possible, to detect for emerging antimi-
crobial resistance. The introduction of real-time polymerase 
chain reaction platforms into clinics will lead to improved 
therapeutic outcomes by enabling minor component resis-
tance to be detected well before conventional culture-based 
techniques (eg, Etest) can identify resistance.
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